Opinion|Videos|September 27, 2024
Frontline Treatment and Sequencing Therapy
Panelists discuss how their institutions approach frontline treatment for transplant-eligible multiple myeloma patients, typically using a combination of novel agents like proteasome inhibitors and immunomodulatory drugs, followed by autologous stem cell transplantation and maintenance therapy, while considering factors such as patient characteristics and treatment response to guide therapy sequencing.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What does your institution use for frontline treatment and how do you sequence therapy for patients who are transplant-eligible?
Advertisement
Related to this article
Persistent symptoms can complicate life after a multiple myeloma treatment response, making routine symptom assessment and targeted supportive care essential.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
2
Community Pharmacists Guide Patients New to Glucose Monitoring
3
Is Less More? Comparing Metronidazole Dosing in Confirmed Anaerobic Infections
4
Two Gene Therapy Approvals Expand Options for Rare Immune Disorders as Access Challenges Persist
5